



Clinical Characteristics and Outcome of Neonates Born to SARS-CoV2 Positive Mothers: An Observation Study from a Single Center in South India

Krithika MV ^{1,*}, Pradeep GCM ¹, Sharanabasavesh Mangalgi ¹ and Sujani BK ²

¹ANeonatal Unit, Department of Pediatrics, Ramaiah Medical College, Bangalore, India

²Department of Obstetrics & Gynaecology, Ramaiah Medical College, Bangalore, India

*Corresponding author: Department of Pediatrics, Ramaiah Medical College, Bangalore, India. Email: krithika.mv@gmail.com

Received 2021 January 23; Revised 2021 December 13; Accepted 2022 February 27.

Abstract

Background: The World Health Organization has declared coronavirus disease 2019 (COVID-19) a pandemic worldwide. Older people, individuals with comorbidities, and pregnant women are more susceptible to this virus, leading to adverse outcomes and mortality.

Methods: Mothers with COVID-19 were divided into two groups of symptomatic and asymptomatic positive cases. Neonates were clinically evaluated and screened at 24 - 48 hours of age for SARS-CoV-2 by real-time polymerase chain reaction. Maternal and neonatal demographics, clinical characteristics, and follow-up at 14 days post-discharge were recorded. The adverse birth outcomes, preterm premature rupture of membrane (PPROM), cesarean section delivery (C-section), and duration of hospital stay were evaluated.

Results: Out of 453 pregnant women, 59 (13.1%) and 394 (86.9%) were positive and negative for SARS-CoV-2, respectively. We subclassified 59 infected pregnant women into two groups symptomatic (10.1%) and asymptomatic (89.8%). The PPRM ($P = 0.001$), gestational diabetes mellitus ($P = 0.006$), C-section ($P = 0.002$), and APGAR score ($P = 0.029$) had a significant association with SARS-CoV-2 presence in mothers and neonates.

Conclusions: None of the neonates from infected pregnant women were infected with SARS-CoV-2, suggesting no negligible risk for mother-to-child transmission of the virus. However, the mother-newborn dyad needs to be followed up further to confirm our results.

Keywords: COVID-19, Newborn, Pregnancy, SARS-CoV-2

1. Background

According to the Ministry of Health and Family Welfare, Government of India, 7,597,063 cases of coronavirus disease 2019 (COVID-19) and 115,197 deaths have been reported until October 2020 in India (1). The major source for the spread of this virus is the respiratory droplets and/or close contact with infected people and family clustering (2). Older people, individuals with comorbidities, and pregnant women are more prone to this virus which causes adverse outcomes and mortality (3). Pregnant women are highly susceptible due to their physiological and immunological changes (4).

Recent systematic reviews and meta-analyses described the various characteristics of COVID-19 positive mothers and their neonates (5-7). Independent prospec-

tive studies, case series, and case reports have yielded inconsistent results about the adverse perinatal outcomes of prematurity, stillbirths, and early pregnancy losses (8-11). A study on 1140 pregnant women in India showed that 88% of pregnant women positive for SARS-CoV-2 were asymptomatic. The researchers concluded that international guidelines are needed for testing (12). Furthermore, a systematic review indicated that maternal mortality rose by 37% during the pandemic compared to before (13). However, only two studies from India reported a significant increase in maternal deaths (14). One study demonstrated a 7% rise in maternal mortality, while the results of another study did not show any significant rise during the pandemic (15).

Neonatal SARS-CoV-2 infections are sporadic, and the

possibility of the vertical transmission of infection from mother to infant is not clear (16, 17). However, studies have found contradictory results on the vertical and/or postnatal transmission of SARS-CoV-2 (18, 19). There is also no conclusive evidence of the transmission of SARS-CoV-2 through the placenta and breast milk (6, 20). Other investigations have shown the presence of SARS-CoV-2 by polymerase chain reaction (PCR) in the upper respiratory tract of neonates with mild respiratory disease (21, 22). Studies assessing the impact of COVID-19 on maternal characteristics, pregnancy outcomes, and vertical transmission were inconsistent.

2. Objectives

The present study was designed to understand the clinical characteristics and outcomes of neonates born to mothers positive for SARS-CoV-2.

3. Methods

This study was conducted during May 1, 2020-September 30, 2020, at Ramaiah Medical College Hospital, Bangalore, Karnataka, India. The flowchart for the recruitment of subjects is presented in Figure 1. All pregnant women delivered at this tertiary care hospital during the study period were included. Informed consent was obtained from all patients prior to the study. The ethical confirmation for the study was taken from the Institutional Ethics Committee (IEC: MSRMC/EC/AP-01/12-2020). Nasopharyngeal swabs from all pregnant women were tested for SARS-CoV-2 using reverse transcriptase (RT)-PCR (NeoDx, Biotech labs kit, India) assay at admission to Labor and Delivery.

All pregnant mothers who were positive for SARS-CoV-2 or were suspected of having SARS-CoV-2 infection were referred to an isolated labor room or isolated operating theatre. The maternal information, including age, preterm premature rupture of membranes (PPROM), gestational diabetes mellitus (GDM), pregnancy-induced hypertension (PIH)/preeclampsia, and antepartum hemorrhage (APH), were obtained from medical records or direct communication with patients and their families. All pregnant women positive for SARS-CoV-2 were divided into two groups, including symptomatic and asymptomatic positive cases. Furthermore, laboratory findings for mothers,

such as cough, PPRM, GDM, PIH/PE, and APH, were evaluated. In addition, some factors for neonates, including birth weight, mode of delivery, CPAP, MV, surfactants, WBC count, platelet count, and C-reactive protein (CRP), were collected.

The neonates born to positive or suspected mothers were shifted to an isolation nursery or neonatal intensive care unit (NICU) based on the clinical condition of the baby. A neonatal throat swab was collected to test for SARS-CoV-2 by RT-PCR at 24 - 48 hours of life. Repeat swab testing was completed only if the baby developed symptoms within 2 weeks of delivery. Neonates were started on expressed breast milk from the mother or formula feeds. Infants having any clinical symptoms were managed based on the standard NICU protocol. If the neonate was asymptomatic and tested negative, discharge was planned along with the mother with the advice to follow up for any symptoms at 2 weeks of life. The follow-up information was obtained by telephone and video consultation with the neonates. If the neonate was asymptomatic and negative for SARS-CoV-2 and the mother was not discharged from the hospital, the option of the baby being discharged with a healthy caretaker (not a primary contact) was discussed with the parents.

3.1. Statistical Analysis

All data were analyzed using the SPSS software version 16 (SPSS Inc., Chicago, IL, USA). Descriptive data are presented as number and percentage, mean and standard deviation, or median and inter-quartile range. The chi-square test was used for categorical variables, an independent *t*-test was utilized for variables with normal distribution, and the Mann-Whitney test was applied for variables with non-normal distribution. *P*-value < 0.05 was considered statistically significant.

4. Results

During the study period, 453 pregnant women were admitted to the hospital mentioned above for delivery and were evaluated by the obstetric team. Among them, 59 (13.1%) women were confirmed with SARS-CoV-2 and underwent diagnostic evaluation, and the remaining 394 (86.9%) were negative for the virus. Table 1 shows the study characteristics comparison between the positive and negative pregnant women. There was a statistically significant difference for PPRM (*P*=0.001) and GDM (*P*=0.006) between




Figure 1. Flowchart of study participants

the pregnant women positive and negative for SARS-CoV-2. However, no significant difference was observed for age, PIH, and APH (Table 1).

Moreover, the characteristics of neonates stratified by maternal SARS-CoV-2 status are presented in Table 2. The mode of delivery was the only characteristic that showed a statistically significant difference between pregnant women with or without SARS-CoV-2 ($P = 0.002$) (Table 2). In addition, among the positive pregnant women, 74.6% of neonates were born by C-section. The other characteristics, such as birth weight, need for NICU admission, need for respiratory support, and the duration of hospital stay, were not found to have significant differences between the

study groups (Table 2).

A total of 59 pregnant women with SARS-CoV-2 were classified into two groups based on being symptomatic (10.1%) or asymptomatic (89.8%), and their clinical characteristics are summarized in Table 3. Cough ($P = 0.001$) and PPROM ($P = 0.024$) had significant associations with SARS-CoV-2 infection in pregnant women. Furthermore, age ($P = 0.655$) and GDM ($P = 0.999$) did not show any significant association with the groups (Table 3). Table 4 demonstrates 60 (1 mother delivered twin babies) characteristics of neonates stratified by maternal symptomatic and asymptomatic SARS-CoV-2. There were no significant differences in the studied characteristics between the symp-

Table 1. Comparison of Maternal Characteristics Between the Groups Positive and Negative for SARS-CoV-2^a

Characteristics	SARS-CoV-2		P-Value
	Negative (N = 394)	Positive (N = 59)	
Age (y)	28.6 ± 4.54	29.1 ± 4.9	0.524
PPROM			0.001
Yes	25 (6.3)	12 (20.3)	
No	369 (93.7)	47 (79.6)	
GDM			0.006
Yes	46 (11.7)	15 (25.4)	
No	348 (88.3)	44 (74.5)	
PIH/PE			1
Yes	71 (18)	11 (18.6)	
No	323 (82)	48 (81.3)	
APH			1
Yes	5 (1.3)	1 (1.69)	
No	389 (98.7)	58 (98.3)	

Abbreviations: PPRM, preterm premature rupture of membranes; GDM, gestational diabetes mellitus; PIH, pregnancy-induced hypertension; PE, preeclampsia; APH, antepartum hemorrhage.

^a Values are expressed as No. (%) or mean ± SD.

tomatic and asymptomatic cases (Table 4).

We reached 52 parents out of 59 confirmed maternal SARS-CoV-2 cases (88%) through phone calls and video consultation by the neonatal team on day 14 of life to determine the neonate's clinical condition and feeding status. Out of 53 neonates (1 pair of twins included) born to mothers positive for SARS-CoV-2, 7 (13%) were on formula feeds, and the rest (87%) were on exclusive breastfeeding. Two neonates were readmitted for exaggerated physiological jaundice needing phototherapy. Both neonates tested negative for SARS-CoV-2 when tested again on their readmission to the NICU.

5. Discussion

We compared the pregnancy outcomes between the pregnant women positive and negative for SARS-CoV-2. In addition, clinical characteristics were compared between the symptomatic and asymptomatic pregnant women infected by SARS-CoV-2. In the present study, an increase was observed in the percentage of C-section delivery among pregnant women with SARS-CoV-2. However, there were no neonates infected by SARS-CoV-2 in either of the study groups. Cough was the only symptom observed in the infected pregnant women. The PPRM was significantly different between positive and negative women and between symptomatic and asymptomatic groups.

Previous studies reported unique physiologic and immunologic changes and augmented risk for several vi-

ral infections, including influenza and SARS during pregnancy (23, 24). Furthermore, a study that compared pregnant and non-pregnant women revealed that pregnant women were more vulnerable to infection and developed grievous disease complications (25). In the current study, the SARS-CoV-2 infection rate among pregnant women was 13%. Another study in Maharashtra, India, on 1140 pregnant women reported 141 participants as positive for SARS-CoV-2, resulting in a prevalence of 12.3%. Variable prevalence rates (0 - 40%) were reported across different hospitals within the state (12). Although several hospital-based investigations showed that SARS infection increased the mortality rate in pregnant women (26), no deaths were reported among 59 confirmed SARS-CoV-2 cases in the current study. However, another study conducted in Hong Kong, China, found that SARS-CoV-2 infection in pregnant women caused higher pregnancy loss rates, prematurity, growth restriction in the fetus, and a 25% fatality rate (23).

The prevalence rate of symptomatic pregnant women was 10.1%, while that of asymptomatic pregnant women was 89.8% in the current study population. The results are in accordance with the previous study conducted in Maharashtra, India, which found the prevalence of symptomatic and asymptomatic pregnant women to be 11.5% and 88.5%, respectively (12). The prevalence of symptomatic and asymptomatic SARS-CoV-2 pregnant women greatly varied across distinct cities. A study on 1148 women hospitalized for SARS-CoV-2 during pregnancy showed that 63% were symptomatic. The incidence of hospital admissions

Table 2. Neonates Characteristics Stratified by Maternal SARS-CoV-2 Status^a

Characteristics	SARS-CoV-2		P-Value
	Negative (N = 402)	Positive (N = 59)	
Gestational age (w)	28.9 ± 4.3	29.1 ± 4.9	0.525
Birth weight (kg)	2.79 ± 0.64	2.9 ± 0.64	0.512
Respiratory support			0.37
Yes	72 (17.9)	14 (23.7)	
No	330 (82.1)	45 (76.2)	
Hospital stay (d)			0.481
Yes	5.42 ± 6.65	5.95 ± 5.21	
NICU			0.604
Yes	81 (20.1)	14 (23.7)	
No	321 (79.8)	45 (76.2)	
Mode of delivery			0.002
LSCS	198 (49.3)	44 (74.6)	
NVD	204 (50.7)	15 (25.4)	
O₂ by hood			0.451
Yes	64 (15.9)	12 (20.3)	
No	338 (84.1)	47 (79.7)	
CPAP			0.406
Yes	27 (6.7)	2 (3.4)	
No	375 (93.3)	57 (96.6)	
MV			0.378
Yes	9 (2.2)	3 (5.1)	
No	393 (97.8)	56 (94.9)	
Surfactant			1
Yes	12 (3)	2 (3.4)	
No	390 (97)	57 (96.6)	
APGAR score	8.39 ± 0.79	8 ± 1.23	0.029

Abbreviations: NICU, neonatal intensive care unit; CPAP, continuous positive airway pressure; MV, mechanical ventilation; APGAR, appearance, pulse, grimace, activity, and respiration

^a Values are expressed as No. (%) or mean ± SD.

for symptomatic SARS-CoV-2 infection was 2 per 1000 maternity and for asymptomatic was 1.2 per 1000 maternity (27).

A study on a large population of 2143 patients showed that over 90% were either asymptomatic or had mild/moderate disease. However, 10.6% of severe cases were reported in the age group under 1 year, indicat-

ing that the risk of infants developing severe respiratory failure may be higher among children (28). So far, there has been no proper conclusion on the intrauterine and breastfeeding transmission of SARS-CoV-2 from mother to infant. Chen et al. tested six SARS-CoV-2-infected neonatal samples of cord blood, amniotic fluid, and throat swabs. These authors showed no evidence of transmission from mother to fetus (18). Furthermore, Liu et al. reported no serological evidence for the mother-to-fetus transmission of the virus. Zhu et al. (29) revealed PCR-negative throat swabs for SARS-CoV-2 in ten neonates. On the other hand, a case report based on positive IgM serology in a neonate suggested intrauterine infection (30).

In our study, maternal comorbidities, such as PPRM, GDM, PIH, and APH, were compared between the groups negative and positive for SARS-CoV-2. We observed a significant difference in GDM between the groups negative and positive for SARS-CoV-2. However, no difference was found between the symptomatic and asymptomatic groups. The Centers for Disease Control reported more diabetes complications in pregnancy among women hospitalized for SARS-CoV-2 infection than those hospitalized for other obstetric reasons (8.1%) (31). A retrospective observational study found 14.3% PIH or preeclampsia cases, 3.6% preeclampsia, and 10.7% GDM among individuals positive for SARS-CoV-2. However, none of these risk factors were significantly different between the pregnant women positive and negative for SARS-CoV-2 (32, 33).

Data is limited concerning the relationship between the mode of delivery and perinatal transmission of COVID-19. Three neonates were born vaginally, and throat swabs on day one of birth were negative for SARS-CoV-2 by PCR (29). Another patient positive for SARS-CoV-2 was negative for the virus tested by vaginal swab during delivery (34). Therefore, the available data suggest no increase in the risk of perinatal vaginal birth to neonates. Several reports on postpartum transmission confirm that neonates can become infected with SARS-CoV-2 through horizontal transmission via respiratory droplets or close contact with parents or caregivers (25, 35). Moreover, the breast milk samples of mothers infected by SARS-CoV-2 had negative PCR results (18). In the current study, no SARS-CoV-2-positive infants were observed, which may be due to strict infection control and prevention procedures implemented during delivery. For example, the immediate separation of infants from infected mothers could be a possible explanation. In our study, the measures to avoid infection transmission

Table 3. Maternal Characteristics Classified by Symptomatic and Asymptomatic

Characteristics	SARS CoV-2 Positive		P-Value
	Symptomatic (N = 6)	Asymptomatic (N = 53)	
Age (y)	21.8 ± 4.8	29.1 ± 4.9	0.655
Cough			0.001
Yes	5	0	
No	1	53	
PPROM			0.024
Yes	4	10	
No	2	43	
GDM			0.999
Yes	2	13	
No	4	40	
PIH/PE			0.344
Yes	0	11	
No	6	42	
APH			1
Yes	0	1	
No	6	52	

Abbreviations: PPRM, preterm premature rupture of membranes; GDM, gestational diabetes mellitus; PIH, pregnancy-induced hypertension; PE, preeclampsia; APH, antepartum hemorrhage.

from infected mothers to neonates might have reduced the exclusive breastfeeding rates at discharge and follow-up. However, the post-discharge advice given to the mothers effectively reduced the rate of postnatal horizontal transmission of the virus, resulting in none of the neonates being symptomatic for SARS-CoV-2 and reduced readmission rates.

This study had some limitations, the first of which was the very small sample size and the low number of SARS-CoV-2 patients. Second, this was a single-center study necessitating the assessment of different populations in the same geographic region. Finally, proper follow-up for the negative patients should be taken into consideration because this is a pandemic disease, and the chance of infection after discharge is high.

5.1. Conclusions

The present study provided evidence for pregnant women infected by SARS-CoV-2 and their neonate's clinical outcomes. There were no neonates infected with SARS-CoV-2 from infected pregnant women. The number of asymptomatic pregnant women was higher than symptomatic cases in the current research. Moreover, an increased percentage of C-section delivery was found among the pregnant women infected by SARS-CoV-2. However, the long-term follow-up of pregnant women and their children and multicenter investigations, which include a large number of samples in different centers across the country, are required to confirm our results. Furthermore, extensive re-

search to evaluate the long-term outcomes and potential of the vertical transmission of SARS-CoV-2 to infants are warranted.

Acknowledgments

The authors would like to thank all the study participants and Ramaiah Medical College Hospital, Bangalore, Karnataka, India, for providing facilities for this study.

Footnotes

Authors' Contribution: KMV developed the original idea and protocol, abstracted and analyzed the data, wrote the manuscript, and was a guarantor. PGCM, SM, and SBK contributed to the development of the protocol, abstracted data, and prepared the manuscript.

Conflict of Interests: The authors declare no conflict of interest.

Data Reproducibility: It was not declared by the authors.

Ethical Approval: The ethical approval was taken from the Institutional Ethical Committee (IEC number MSRMC/EC/AP-01/12-2020) (<https://msrhc.ac.in/research/ethics-committee/>)

Funding/Support: There was no funding/support for this manuscript.

Informed Consent: Informed consent was obtained from all study participants prior to the study.

Table 4. Neonates Characteristics Stratified by Symptomatic and Asymptomatic Mothers

Characteristics	SARS-CoV-2 Positive		P-Value
	Symptomatic (N = 6)	Asymptomatic (N = 53)	
Gestational age (w)	28.2 ± 4.9	27.8 ± 3.1	0.656
Birth weight (kg)	2.7 ± 0.54	2.9 ± 0.6	0.446
Mode of delivery			1
LSCS	5	39	
NVD	1	14	
O₂ by hood			0.091
Yes	3	9	
No	3	44	
CPAP			1
Yes	0	2	
No	6	51	
MV			1
Yes	0	3	
No	6	50	
Surfactants			1
Yes	0	2	
No	6	51	
CRP			0.67
Positive	5	38	
Negative	1	15	
Discharge weight	2.6 ± 0.52	2.8 ± 0.5	0.284
WBC	14616 ± 5998	22266 ± 28976	0.109
Platelet	246666 ± 6742	242076 ± 76509	0.881
APGAR score	8 ± 0.7	8.15 ± 0.8	0.659

Abbreviations: CPAP, continuous positive airway pressure; MV, mechanical ventilation; CRP, C-reactive protein; WBC, white blood cells; APGAR, appearance, pulse, grimace, activity, and respiration.

References

- World Health Organization (India). *Novel CoronaVirus Disease (COVID 19)*. World Health Organization (India); 2020.
- Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. *Environ Res*. 2020;188:109819. doi: [10.1016/j.envres.2020.109819](https://doi.org/10.1016/j.envres.2020.109819). [PubMed: [32569870](https://pubmed.ncbi.nlm.nih.gov/32569870/)]. [PubMed Central: [PMC7293495](https://pubmed.ncbi.nlm.nih.gov/PMC7293495/)].
- Epidemiology Working Group for Ncip Epidemic Response CCFDC; Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2020;41(2):145-51. doi: [10.3760/cma.j.issn.0254-6450.2020.02.003](https://doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003). [PubMed: [32064853](https://pubmed.ncbi.nlm.nih.gov/32064853/)].
- Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. *J Reprod Immunol*. 2020;139:103122. doi: [10.1016/j.jri.2020.103122](https://doi.org/10.1016/j.jri.2020.103122). [PubMed: [32244166](https://pubmed.ncbi.nlm.nih.gov/32244166/)]. [PubMed Central: [PMC7156163](https://pubmed.ncbi.nlm.nih.gov/PMC7156163/)].
- Dubey P, Reddy SY, Manuel S, Dwivedi AK. Maternal and neonatal characteristics and outcomes among COVID-19 infected women: An updated systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol*. 2020;252:490-501. doi: [10.1016/j.ejogrb.2020.07.034](https://doi.org/10.1016/j.ejogrb.2020.07.034). [PubMed: [32795828](https://pubmed.ncbi.nlm.nih.gov/32795828/)]. [PubMed Central: [PMC7373687](https://pubmed.ncbi.nlm.nih.gov/PMC7373687/)].
- Trippella G, Ciarcia M, Ferrari M, Buzzatti C, Maccora I, Azzari C, et al. COVID-19 in Pregnant Women and Neonates: A Systematic Review of the Literature with Quality Assessment of the Studies. *Pathogens*. 2020;9(6). doi: [10.3390/pathogens9060485](https://doi.org/10.3390/pathogens9060485). [PubMed: [32570959](https://pubmed.ncbi.nlm.nih.gov/32570959/)]. [PubMed Central: [PMC7350364](https://pubmed.ncbi.nlm.nih.gov/PMC7350364/)].
- Chi H, Chiu NC, Tai YL, Chang HY, Lin CH, Sung YH, et al. Clinical features of neonates born to mothers with coronavirus disease-2019: A systematic review of 105 neonates. *J Microbiol Immunol Infect*. 2021;54(1):69-76. doi: [10.1016/j.jmii.2020.07.024](https://doi.org/10.1016/j.jmii.2020.07.024). [PubMed: [32847748](https://pubmed.ncbi.nlm.nih.gov/32847748/)]. [PubMed Central: [PMC7427525](https://pubmed.ncbi.nlm.nih.gov/PMC7427525/)].
- Antoun L, Taweel NE, Ahmed I, Patni S, Honest H. Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: A prospective cohort study. *Eur J Obstet Gynecol Reprod Biol*. 2020;252:559-62. doi: [10.1016/j.ejogrb.2020.07.008](https://doi.org/10.1016/j.ejogrb.2020.07.008). [PubMed: [32732059](https://pubmed.ncbi.nlm.nih.gov/32732059/)]. [PubMed Central: [PMC7362841](https://pubmed.ncbi.nlm.nih.gov/PMC7362841/)].
- Yang P, Wang X, Liu P, Wei C, He B, Zheng J, et al. Clinical characteristics and risk assessment of newborns born to mothers with COVID-19. *J Clin Virol*. 2020;127:104356. doi: [10.1016/j.jcv.2020.104356](https://doi.org/10.1016/j.jcv.2020.104356). [PubMed: [32302955](https://pubmed.ncbi.nlm.nih.gov/32302955/)]. [PubMed Central: [PMC7194834](https://pubmed.ncbi.nlm.nih.gov/PMC7194834/)].
- Buonsenso D, Costa S, Sanguinetti M, Cattani P, Posteraro B, Marchetti S, et al. Neonatal Late Onset Infection with Severe Acute Respiratory Syndrome Coronavirus 2. *Am J Perinatol*. 2020;37(8):869-72. doi: [10.1055/s-0040-1710541](https://doi.org/10.1055/s-0040-1710541). [PubMed: [32359227](https://pubmed.ncbi.nlm.nih.gov/32359227/)]. [PubMed Central: [PMC7356068](https://pubmed.ncbi.nlm.nih.gov/PMC7356068/)].
- Yang H, Sun G, Tang F, Peng M, Gao Y, Peng J, et al. Clinical features and outcomes of pregnant women suspected of coronavirus disease 2019. *J Infect*. 2020;81(1):e40-4. doi: [10.1016/j.jinf.2020.04.003](https://doi.org/10.1016/j.jinf.2020.04.003). [PubMed: [32294503](https://pubmed.ncbi.nlm.nih.gov/32294503/)]. [PubMed Central: [PMC7152867](https://pubmed.ncbi.nlm.nih.gov/PMC7152867/)].
- Waghmare R, Gajbhiye R, Mahajan NN, Modi D, Mukherjee S, Mahale SD. Universal screening identifies asymptomatic carriers of SARS-CoV-2 among pregnant women in India. *Eur J Obstet Gynecol Reprod Biol*. 2021;256:503-5. doi: [10.1016/j.ejogrb.2020.09.030](https://doi.org/10.1016/j.ejogrb.2020.09.030). [PubMed: [33393481](https://pubmed.ncbi.nlm.nih.gov/33393481/)]. [PubMed Central: [PMC7510530](https://pubmed.ncbi.nlm.nih.gov/PMC7510530/)].
- Chmielewska B, Barratt I, Townsend R, Kalafat E, van der Meulen J, Gurol-Urganci I, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. *Lancet Glob Health*. 2021;9(6):e759-72. doi: [10.1016/S2214-109X\(21\)00079-6](https://doi.org/10.1016/S2214-109X(21)00079-6).
- Kumari V, Mehta K, Choudhary R. COVID-19 outbreak and decreased hospitalisation of pregnant women in labour. *Lancet Glob Health*. 2020;8(9):e1116-7. doi: [10.1016/S2214-109X\(20\)30319-3](https://doi.org/10.1016/S2214-109X(20)30319-3). [PubMed: [32679037](https://pubmed.ncbi.nlm.nih.gov/32679037/)]. [PubMed Central: [PMC7833326](https://pubmed.ncbi.nlm.nih.gov/PMC7833326/)].
- Goyal M, Singh P, Singh K, Shekhar S, Agrawal N, Misra S. The effect of the COVID-19 pandemic on maternal health due to delay in seeking health care: Experience from a tertiary center. *Int J Gynaecol Obstet*. 2021;152(2):231-5. doi: [10.1002/ijgo.13457](https://doi.org/10.1002/ijgo.13457). [PubMed: [33128794](https://pubmed.ncbi.nlm.nih.gov/33128794/)]. [PubMed Central: [PMC9087665](https://pubmed.ncbi.nlm.nih.gov/PMC9087665/)].
- Arora N, Sadovsky Y, Dermody TS, Coyne CB. Microbial Vertical Transmission during Human Pregnancy. *Cell Host Microbe*. 2017;21(5):561-7.

- doi: [10.1016/j.chom.2017.04.007](https://doi.org/10.1016/j.chom.2017.04.007). [PubMed: [28494237](https://pubmed.ncbi.nlm.nih.gov/28494237/)]. [PubMed Central: [PMC6148370](https://pubmed.ncbi.nlm.nih.gov/PMC6148370/)].
17. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. *Am J Reprod Immunol.* 2015;**73**(3):199–213. doi: [10.1111/aji.12355](https://doi.org/10.1111/aji.12355). [PubMed: [25582523](https://pubmed.ncbi.nlm.nih.gov/25582523/)]. [PubMed Central: [PMC4610031](https://pubmed.ncbi.nlm.nih.gov/PMC4610031/)].
 18. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet.* 2020;**395**(10226):809–15. doi: [10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3). [PubMed: [32151335](https://pubmed.ncbi.nlm.nih.gov/32151335/)]. [PubMed Central: [PMC7159281](https://pubmed.ncbi.nlm.nih.gov/PMC7159281/)].
 19. Liu D, Li L, Wu X, Zheng D, Wang J, Yang L, et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis. *AJR Am J Roentgenol.* 2020;**215**(1):127–32. doi: [10.2214/AJR.20.23072](https://doi.org/10.2214/AJR.20.23072). [PubMed: [32186894](https://pubmed.ncbi.nlm.nih.gov/32186894/)].
 20. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. *Front Med.* 2020;**14**(2):193–8. doi: [10.1007/s11684-020-0772-y](https://doi.org/10.1007/s11684-020-0772-y). [PubMed: [32285380](https://pubmed.ncbi.nlm.nih.gov/32285380/)]. [PubMed Central: [PMC7152620](https://pubmed.ncbi.nlm.nih.gov/PMC7152620/)].
 21. Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet Infect Dis.* 2020;**20**(5):559–64. doi: [10.1016/s1473-3099\(20\)30176-6](https://doi.org/10.1016/s1473-3099(20)30176-6).
 22. Ferrazzi E, Frigerio L, Savasi V, Vergani P, Prefumo F, Barresi S, et al. Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis. *BJOG.* 2020;**127**(9):1116–21. doi: [10.1111/1471-0528.16278](https://doi.org/10.1111/1471-0528.16278). [PubMed: [32339382](https://pubmed.ncbi.nlm.nih.gov/32339382/)]. [PubMed Central: [PMC7267664](https://pubmed.ncbi.nlm.nih.gov/PMC7267664/)].
 23. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am J Obstet Gynecol.* 2004;**191**(1):292–7. doi: [10.1016/j.ajog.2003.11.019](https://doi.org/10.1016/j.ajog.2003.11.019). [PubMed: [15295381](https://pubmed.ncbi.nlm.nih.gov/15295381/)]. [PubMed Central: [PMC7137614](https://pubmed.ncbi.nlm.nih.gov/PMC7137614/)].
 24. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. *Lancet.* 2009;**374**(9688):451–8. doi: [10.1016/S0140-6736\(09\)61304-0](https://doi.org/10.1016/S0140-6736(09)61304-0). [PubMed: [19643469](https://pubmed.ncbi.nlm.nih.gov/19643469/)].
 25. Donders F, Lonnee-Hoffmann R, Tsiakalos A, Mendling W, Martinez de Oliveira J, Judlin P, et al. ISIDOG Recommendations Concerning COVID-19 and Pregnancy. *Diagnostics (Basel).* 2020;**10**(4). doi: [10.3390/diagnostics10040243](https://doi.org/10.3390/diagnostics10040243). [PubMed: [32338645](https://pubmed.ncbi.nlm.nih.gov/32338645/)]. [PubMed Central: [PMC7235990](https://pubmed.ncbi.nlm.nih.gov/PMC7235990/)].
 26. Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. *Viruses.* 2020;**12**(2). doi: [10.3390/v12020194](https://doi.org/10.3390/v12020194). [PubMed: [32050635](https://pubmed.ncbi.nlm.nih.gov/32050635/)]. [PubMed Central: [PMC7077337](https://pubmed.ncbi.nlm.nih.gov/PMC7077337/)].
 27. Vousden N, Bunch K, Morris E, Simpson N, Gale C, O'Brien P, et al. The incidence, characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS-CoV-2 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS). *PLoS One.* 2021;**16**(5). e0251123. doi: [10.1371/journal.pone.0251123](https://doi.org/10.1371/journal.pone.0251123). [PubMed: [33951100](https://pubmed.ncbi.nlm.nih.gov/33951100/)]. [PubMed Central: [PMC8099130](https://pubmed.ncbi.nlm.nih.gov/PMC8099130/)].
 28. Eastin C, Eastin T. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China: Dong Y, Mo X, Hu Y, et al. *Pediatrics.* 2020. *J Emerg Med.* 2020;**58**(4):712–3.
 29. Liu Y, Chen H, Tang K, Guo Y. Withdrawn: Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. *J Infect.* 2020. doi: [10.1016/j.jinf.2020.02.028](https://doi.org/10.1016/j.jinf.2020.02.028). [PubMed: [32145216](https://pubmed.ncbi.nlm.nih.gov/32145216/)]. [PubMed Central: [PMC7133645](https://pubmed.ncbi.nlm.nih.gov/PMC7133645/)].
 30. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr.* 2020;**9**(1):51–60. doi: [10.21037/tp.2020.02.06](https://doi.org/10.21037/tp.2020.02.06). [PubMed: [32154135](https://pubmed.ncbi.nlm.nih.gov/32154135/)]. [PubMed Central: [PMC7036645](https://pubmed.ncbi.nlm.nih.gov/PMC7036645/)].
 31. Panagiotakopoulos L, Myers TR, Gee J, Lipkind HS, Kharbanda EO, Ryan DS, et al. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;**69**(38):1355–9. doi: [10.15585/mmwr.mm6938e2](https://doi.org/10.15585/mmwr.mm6938e2). [PubMed: [32970660](https://pubmed.ncbi.nlm.nih.gov/32970660/)]. [PubMed Central: [PMC7727498](https://pubmed.ncbi.nlm.nih.gov/PMC7727498/)].
 32. Liu C, Andrusier M, Silver M, Applewhite L, Clare CA. Effect of SARS-CoV-2 Infection on Pregnancy Outcomes in an Inner-City Black Patient Population. *J Community Health.* 2021;**46**(5):1029–35. doi: [10.1007/s10900-021-00988-z](https://doi.org/10.1007/s10900-021-00988-z). [PubMed: [33855649](https://pubmed.ncbi.nlm.nih.gov/33855649/)]. [PubMed Central: [PMC8046575](https://pubmed.ncbi.nlm.nih.gov/PMC8046575/)].
 33. Narang K, Enninga EAL, Gunaratne M, Ibirogba ER, Trad ATA, Elrefaei A, et al. SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review. *Mayo Clin Proc.* 2020;**95**(8):1750–65. doi: [10.1016/j.mayocp.2020.05.011](https://doi.org/10.1016/j.mayocp.2020.05.011). [PubMed: [32753148](https://pubmed.ncbi.nlm.nih.gov/32753148/)]. [PubMed Central: [PMC7260486](https://pubmed.ncbi.nlm.nih.gov/PMC7260486/)].
 34. Fan C, Lei D, Fang C, Li C, Wang M, Liu Y, et al. Perinatal Transmission of 2019 Coronavirus Disease-Associated Severe Acute Respiratory Syndrome Coronavirus 2: Should We Worry? *Clin Infect Dis.* 2021;**72**(5):862–4. doi: [10.1093/cid/ciaa226](https://doi.org/10.1093/cid/ciaa226). [PubMed: [32182347](https://pubmed.ncbi.nlm.nih.gov/32182347/)]. [PubMed Central: [PMC7184438](https://pubmed.ncbi.nlm.nih.gov/PMC7184438/)].
 35. Shiu EYC, Leung NHL, Cowling BJ. Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention. *Curr Opin Infect Dis.* 2019;**32**(4):372–9. doi: [10.1097/QCO.0000000000000563](https://doi.org/10.1097/QCO.0000000000000563). [PubMed: [31259864](https://pubmed.ncbi.nlm.nih.gov/31259864/)].